Continuing Education Activity

Scabies is a highly contagious skin infestation caused by Sarcoptes scabiei var. hominis, a mite that burrows into human skin and produces severe itching, commonly referred to as nocturnal pruritus. Transmission occurs primarily through direct skin-to-skin contact, though contaminated materials can occasionally serve as a vector. Diagnosis can be challenging, as some patients present with subtle findings, whereas others show the classic triad of exposure history, intense night-time itching, and symptomatic close contacts. Though treatment is straightforward, untreated scabies can lead to significant complications, including secondary bacterial infections, abscesses, and poststreptococcal glomerulonephritis. Globally, scabies is an essential public health issue, particularly in low-income regions, and was recognized by the World Health Organization in 2017 as a neglected tropical disease due to its disproportionate burden on impoverished populations.

This activity provides an overview of the mite's biology, the clinical and epidemiological impact of scabies, diagnostic strategies, treatment options, and infection control measures. This activity also highlights the importance of an interprofessional team approach, equipping healthcare professionals with the knowledge to recognize, manage, and prevent scabies in both individual patients and at the community level.

Objectives:

• Identify the clinical features of scabies, including subtle, age-specific, and atypical presentations.
• Implement evidence-based treatment regimens tailored to patient age, comorbidities, and severity of disease.
• Apply infection-control measures to prevent transmission in healthcare and community settings.
• Collaborate with interprofessional teams, including nursing, pharmacy, and public health, to manage individual cases and outbreaks.

Introduction

Scabies is a highly contagious skin condition caused by infestation with the mite Sarcoptes scabiei var. hominis. As an obligate ectoparasite, the mite burrows into human skin and, weeks after the initial infection, triggers intense nocturnal pruritus. Transmission occurs primarily through skin-to-skin contact, placing children, family members, and individuals with close physical interactions at the highest risk of infection.

Recognized as a neglected tropical disease by the World Health Organization in 2017, scabies remains a significant public health concern in many developing regions due to its complications. Without timely intervention, the infection rarely resolves spontaneously, resulting in persistent disease, outbreaks, long-term morbidity, and an increased economic burden.[1] Early recognition and treatment are therefore essential to prevent adverse outcomes. 

Etiology

The mite responsible for scabies, S scabiei var. hominis—commonly referred to as scale mite or itch mite—is an obligate ectoparasite belonging to the class Arachnida, order Sarcoptiformes, and family Sarcoptidae.[2]

Mites are tiny, 8-legged arthropods, invisible to the naked eye. Female mites are about twice the size of males, measuring up to 0.45 × 0.35 mm. Adults mate on the human skin, and infestation begins when the female penetrates the epidermis. Her saliva lyses the stratum corneum, allowing her to burrow and ingest intercellular fluid that accumulates within the tunnel. She lays 2 to 4 eggs per day and excretes fecal pellets (scybala) along burrows, which may extend 1 to 10 mm. Adult mites typically survive for 1 to 2 months. Within 2 to 4 days, 6-legged larvae hatch, create new burrows, and wander on the skin for 14 to 17 days before molting into nymphs and then adults.

Mites depend on host serum for survival; outside the human body, immature forms can survive for up to 9 days at temperatures ranging from 15 to 25 °C and relative humidity levels of 25% to 97%. These mites remain infective for approximately 50% to 66% referenced time period.[2]

Transmission of scabies mites to another human host typically requires 10 to 15 minutes of direct skin-to-skin contact, such as during sexual activity. In classic scabies, where the mite burden is low, spread via fomites (eg, clothing and bedding) is uncommon; however, fomite transmission occurs more frequently in cases of crusted scabies.

Epidemiology

The estimated global prevalence of scabies is approximately 300 million cases annually.[3][4] This substantial burden underscores the need for enhanced public health measures, early diagnosis, and timely treatment to mitigate transmission and prevent complications.

Scabies affects both genders equally but occurs more commonly in children and young adults. In East and Southeast Asia, the highest disability-adjusted life years are observed in children aged 1 to 4, followed by adults older than 70.[5] Scabies remains a public health concern in low-income countries and was declared a neglected skin disease by the World Health Organization in 2017.[4] The highest prevalence occurs in Africa, South America, Australia, and Southeast Asia, where the disease is endemic. Contributing risk factors include poverty, poor nutritional status, homelessness, crowding, and limited access to water and sanitation.[3] 

Scabies occurs more sporadically in high-income countries. In the United States, no national prevalence data exist, as only outbreaks are reportable to local health departments. In industrialized nations, outbreaks have been documented in schools, child-care facilities, long-term acute care facilities, retirement homes, hospitals, correctional facilities, military and refugee camps, and other overcrowded settings.[3]

Since the early 2000s, several Western European countries have reported a rising incidence in the general population, with travel, refugee status, and the COVID-19 pandemic being identified as contributing factors, likely due to lockdown-related risks. Infestations are also more frequent during colder months, particularly winter and early spring, a pattern attributed to closer indoor contact and prolonged mite survival in cooler conditions.[2][6][2]

Pathophysiology

The pathophysiology of scabies reflects both direct mite activity and the host immune response. As female mites burrow into the stratum corneum, they lay eggs, deposit fecal pellets, and eventually die. The resulting mite antigens trigger an immune and inflammatory response within the dermis. Notably, not all treatment options effectively penetrate the skin to kill the eggs, potentially allowing reinfestation after therapy.[2][3][7]

The hallmark clinical manifestations of scabies—intense pruritus and papular skin lesions—are driven by a delayed type IV hypersensitivity reaction. Symptom onset depends on the host's immune status—in primary infections, signs may appear within 4 to 10 weeks, whereas in previously sensitized individuals, symptoms can develop within hours to days.[2] This latency allows for a prolonged asymptomatic but transmissible period.[6] Characteristic papules are tunnel- or comma-shaped, measuring a few millimeters to 1 cm in length. Infestations typically begin in areas of thin skin, such as interdigital folds, areolae, the umbilical region, and the penile shaft.[3]

Clinically, scabies presents in 2 primary forms—classic (ordinary), which may include a nodular variant, and crusted scabies. A rare severe manifestation in bullous form has also been described.[8] The host's immune status and extent of skin involvement largely determine the mite burden.[9]

In classic scabies, an individual typically harbors only 10 to 15 mites. The nodular form, a variant of classic scabies, is characterized by erythematous, pruritic nodules that preferentially develop in moist, thin-skinned areas such as the axillae and groin. These nodules are thought to represent a hypersensitivity reaction to the presence of the female mite.

Crusted scabies occurs primarily in immunocompromised individuals, including those with diabetes mellitus, HIV, older age, or those receiving immunosuppressive therapy.[9][10] Unlike classic scabies, individuals affected by this condition may harbor millions of mites and are therefore highly contagious. Even brief contact with patients or contaminated materials can result in the transmission of infection. Clinically, crusted scabies presents with hyperkeratotic plaques that may be diffuse or localized to the palms, soles, and subungal areas. The presentation of crusted scabies can mimic erythroderma, psoriasis, eczema, seborrheic dermatitis, or pityriasis rubra pilaris.[2]

Histopathology

In routine practice, scabies is diagnosed clinically, and a punch biopsy is rarely required. In classic scabies with a low mite burden, biopsy specimens often fail to capture mites. When present, mites and eggs may be identified within the reticular dermis, accompanied by an inflammatory infiltrate. The epidermis typically shows marked scale and crust, along with a serous exudate, neutrophils, and eosinophils.[2]

History and Physical

Pruritus affecting multiple family members or close contacts should always raise clinical suspicion for scabies. However, patients may present with only subtle signs, may not report a history of exposure, and may lack classic features such as nocturnal pruritus or affected close contacts.[4] Severe itching can lead to insomnia, negatively impacting school and work performance, whereas visible lesions often carry social stigma, all contributing to a reduced quality of life. A high index of suspicion is especially warranted in very young children, older adults, and immunocompromised individuals, who may be paucisymptomatic yet serve as mite reservoirs for ongoing transmission. 

In classic scabies, examination findings include a polymorphous rash composed of excoriated papules, eczematous or lichenified plaques, and nodules (see Image. Rash and Scabies Sites). Pathognomonic burrows consisting of short, wavy white lines with a vesicle or erosion at the distal end that harbors the mite are uncommon and often difficult to detect.

In children younger than 2, lesions may include vesicles and frequently involve the web spaces of the fingers, wrists, and trunk; unlike in adults, the scalp, face, palms, and soles may also be affected. In adults, common sites of mite burrowing include intertriginous areas, flexural surfaces of the wrists, interdigital space, axillae, umbilicus,  beltline, nipples and areolae, buttocks, scrotum, and the penile shaft (see Image. Scabies Burrows).[2]

Chronic scratching over weeks to months can result in excoriations, encrustation, lichenification, prurigo nodularis, and secondary bacterial superinfection, a process known as impetiginization. Superimposed cellulitis presents with painful, erythematous skin, whereas honey-colored yellow crusts characterize impetigo.[4][9].

Crusted scabies may involve hands and feet, including the palms and soles, as well as the head, earlobes, and toenails (see Image. Crusted Scabies).[11] The extensive distribution and thick crusts in these areas often make the condition difficult to recognize and treat, contributing to its high transmissibility and risk of outbreaks. 

Evaluation

Scabies is primarily diagnosed through recognition of the characteristic rash (see Image. Scabies and Scaly Rash) in the context of a supportive patient history. In 2020, the International Alliance for the Control of Scabies published consensus diagnostic criteria for classic scabies, outlining 3 levels of ascending diagnostic certainty:

• Suspected scabies: Typical lesions in a typical distribution, plus 1 history feature
• Clinical scabies: The above, plus visible burrows
• Confirmed scabies: Previous criteria, plus visualization of mites, eggs, or feces

The open-access publication contains useful instructional images.[11] 

Scabies can be confirmed by visualizing mites under a microscope in skin scrapings from the stratum corneum. Unfortunately, this method is time-consuming and has limited sensitivity, due to the high chance of sampling errors.[11]

Dermoscopy, also known as dermatoscopy, is a commonly used noninvasive diagnostic tool in dermatology practices across the United States.[3] This handheld device provides up to ×10 magnification, allowing for the visualization of burrow structures, often described as resembling a jetliner trail or a delta-wing jet. Compared to skin scrapings, dermoscopy offers several advantages—its noninvasive nature makes it better tolerated by children, sensitive patients, and those reluctant to undergo scrapings; it is quick and simple to perform; and it reduces the risk of accidental exposure to bloodborne pathogens. Dermoscopy is also helpful for posttreatment evaluation, as it can detect viable mites in cases of persistent infestation or treatment failure. Limitations include difficulty visualizing burrows on dark skin or in hairy areas, as well as challenges when examining the genital region.[11] 

Videodermatoscopy uses high-magnification video cameras (×10 to ×1000) to examine the skin surface up to the superficial dermis. This technique enables the visualization of burrows, mites, eggs, larvae, and feces.[3] However, its use is limited due to high cost and reduced effectiveness in impetigo lesions. Videodermatoscopy is not widely available in most US practices and remains uncommon in routine clinical settings.[11]

Although a skin biopsy can confirm the diagnosis, the Alliance for the Control of Scabies does not recommend it as standard practice. Other diagnostic methods, such as polymerase chain reaction, are not yet available for routine use.[11]

Treatment / Management

First-line therapies include topical permethrin and oral ivermectin, both of which demonstrate comparable efficacy and superior outcomes compared to alternative treatments.[7] Permethrin is generally recommended as the initial therapy due to its safety profile, including use in children older than 2 months and pregnant women. Oral ivermectin, although not approved by the Food and Drug Administration (FDA) for the treatment of scabies, is particularly useful in cases of crusted scabies, institutional outbreaks, or when topical therapy is impractical.

Topical permethrin 5% cream is typically applied once weekly for 2 weeks, for a total of 2 treatments. The cream is occasionally associated with poor patient compliance, rare allergic reactions, and, in some cases, scabies resistance.[4] An added benefit of permethrin therapy is its indirect effect on clothing and bedding through residual activity. In pediatric populations, permethrin is approved for use in children 2 months and older, whereas sulfur ointment (5%-10%) applied for 3 consecutive days and repeated after 2 weeks is a safe alternative for infants younger than 2 months.[12] For optimal effectiveness, the cream should be applied to the individual and all household contacts. The cream should also be applied to the entire body surface from the neck down, including under the nails. In infants and young children, it should also be applied to the scalp, hairline, face, and ears, while avoiding the eyes and mouth.

Oral ivermectin at a dose of 200 μg/kg, repeated after 14 days, is an effective alternative to permethrin. This drug is approved for use in children older than 10 years and weighing more than 15 kg. Ivermectin is considered scabistatic rather than scabicidal, as it has limited ovicidal activity; the second dose is necessary to kill newly hatched mites. The advantages of ivermectin include convenience, ease of administration, a favorable adverse effect profile, and higher compliance rates compared to topical therapy. The tablet formulation also minimizes the risk of misuse or inadequate coverage associated with topical permethrin.[4] In outbreak settings, systemic ivermectin has demonstrated superiority over topical permethrin, making it particularly valuable for controlling transmission in high-risk environments, such as homeless shelters, correction facilities, and healthcare facilities.[7] However, safety concerns remain regarding its use in pregnant women and children weighing less than 15 kg, and resistance has been reported with repeated or prolonged courses.[6]

In crusted scabies, combination therapy is recommended. Options include 5% topical permethrin cream applied to the entire body daily for 1 week, then twice weekly until cure, or 25% topical benzyl benzoate applied for 24 hours, each combined with oral ivermectin 200 μg/kg given on days 1, 2, 8, 9, and 15. Adjunctive keratolytic agents such as urea or salicylic acid are also recommended to enhance the penetration of topical therapies.[12] Topical benzyl benzoate is additionally considered safe to use in pregnancy and in children.[13]

Topical ivermectin lotion 1% is considered another, though less effective, alternative to permethrin. This lotion is applied to the entire body and washed off after 8 to 14 hours, with a repeat application performed after 1 week if symptoms persist. Spinosad 0.9% topical suspension, an insecticide isolated from a bacterium growing on sugar cane, and crotamiton 10% cream, applied on 2 consecutive days and repeated after 2 weeks, are FDA-approved options in the United States, including for use in pregnant women and children.[13] 

Synergized pyrethrins, which combine pyrethrins with the synergist piperonyl butoxide, show a scabicidal cure rate only slightly lower than that of permethrin and were associated with the lowest probability of adverse effects in a recent network meta-analysis. These agents are FDA-approved for the treatment of lice and are available over the counter. In contrast, malathion 0.5% lotion has shown low cure rates and has been classified as probably carcinogenic to humans by the International Agency for Research on Cancer.[14]

Lindane 1% is reserved as an alternative regimen only when first-line therapies are not tolerated or have failed, due to its potential for neurotoxicity and hematologic adverse effects. The use of lindane 1% is contraindicated in children younger than 10, pregnant or breastfeeding women, and those with extensive dermatitis.[12]

Treatment failure and recurrence are not uncommon, and identifying the underlying cause is essential to prevent reinfestation and limit outbreaks. Common reasons include failure to treat close contacts simultaneously, inadequate decontamination of bedding and clothing, and nonadherence to the treatment regimen, especially when contacts are asymptomatic. In crusted scabies, treatment failure may result from ivermectin-resistant Sarcoptes mites. In such cases, moxidectin has been recommended as an alternative therapy.[9]

Differential Diagnosis

The clinical presentation of classical scabies may mimic many other pruritic papulovesicular skin conditions, especially when impetiginized.[15] Scabies can coexist with, or be misdiagnosed as, irritant dermatitis, contact dermatitis, and atopic eczema. Infestations caused by fleas, bedbugs, or chiggers (Trombicula species, a type of mite) should also be considered.

In crusted scabies, the differential diagnosis includes hyperkeratotic eczema, dyshidrotic eczema, psoriasis, and Darier disease. In bullous scabies, lupus erythematosus, bullous impetigo, and pemphigus vulgaris must be excluded.[8][11][16][11]

Prognosis

In immunocompetent patients, treatment of both the individual and their close contacts or family members is associated with an excellent prognosis, with complete recovery expected in most cases. Without appropriate therapy, scabies can persist chronically, spread to others, and trigger outbreaks within the community.

Complications

The main complications of scabies include persistent pruritus, insomnia, and secondary bacterial infection. Impetigo may occur due to Staphylococcus aureus or Group A Streptococcus (Streptococcus pyogenes). A synergistic relationship exists between scabies mites and S pyogenes. Burrowing mites release complement-inhibiting proteins that impair opsonization, enabling the bacteria to evade immune defenses and proliferate.[1] Untreated superinfections can progress to cellulitis, lymphadenitis, abscess formation, poststreptococcal glomerulonephritis, and community outbreaks.[4] Severe outcomes such as rheumatic fever, rheumatic heart disease, and even death have also been reported.[8]

Patients commonly report persistent itching after treatment, which may result from treatment failure, misdiagnosis, or cutaneous irritation. Other posttreatment complaints include an id reaction, also known as auto-eczematization, and epidermal changes caused by topical treatments. Permethrin cream contains several potential allergens, including formaldehyde and permethrin, as well as components of the cream base. Transient pruritus may also occur following oral ivermectin therapy, attributed to the mass release of mite antigens during their destruction.[4]

Deterrence and Patient Education

Scabies spreads rapidly through close skin-to-skin contact, and less commonly, via contaminated clothing or bed linens. Effective management requires prompt treatment of affected individuals and their close contacts, as well as decontamination of bedding, towels, and clothing. 

In crowded settings, isolation is critical to preventing further transmission. Personal items should be machine-washed in hot water at a minimum of 75 °C and dried on a high-heat setting. Prophylactic topical therapy may also be administered to close contacts to reduce the risk of reinfestation.[15][10]

Pearls and Other Issues

Key facts to keep in mind about scabies include the following:

• Etiology: Caused by S scabiei var hominis
• Transmission: Spread mainly by prolonged skin-to-skin contact (10-15 min); Fomite spread is rare in classic scabies but common in crusted scabies
• Female mite burrows in the stratum corneum, lays eggs, and leaves fecal pellets
• Immune response: Type IV hypersensitivity reaction causes pruritus and rash
• Symptom onset:

  • Primary infection: Symptoms after 4-6 weeks
  • Reinfestation: Symptoms within hours to days

• Hallmark symptom: Intense nocturnal pruritus
• Burrows: Thin, wavy lines with a papule or vesicle at one end
• Common sites: Finger webs, wrists, axillae, umbilicus, waistline, buttocks, male genitals, and areolae
• Pediatric considerations: In infants and young children, the scalp, face, palms, and soles may also be affected
• Variants: Nodular scabies, crusted scabies (Norwegian), and rare bullous scabies
• Diagnosis: Primarily clinical; skin scrapings can reveal mites, eggs, or feces but are insensitive; dermoscopy shows the jetliner trail sign
• Treatment:

  • First-line: Permethrin 5% cream (repeat in 7 days)
  • Oral ivermectin 200 μg/kg (repeat in 14 days) for outbreaks, crusted scabies, or topical failure
  • Sulfur ointment for infants younger than 2 months
  • Crusted scabies: Combination therapy with permethrin, ivermectin, and keratolytics

• Contact management: All close contacts must be treated at the same time
• Environmental measures: Bedding and clothes should be washed hot or sealed in plastic bags for several days [4][12]
• Complications: Persistent itching, secondary bacterial infection, impetigo, cellulitis, and abscesses; group A strep superinfection can cause post-streptococcal glomerulonephritis and rheumatic fever
• Post-scabietic itch: May last weeks and does not mean treatment failure

Enhancing Healthcare Team Outcomes

Management of scabies requires an interprofessional team throughout the course of the disease. Early recognition and accurate diagnosis are crucial for ensuring effective patient care. Nurses and social workers often serve as the first point of contact and may suspect scabies during initial interactions, such as taking vital signs, assisting with hygiene, or helping patients change clothing. If any team member suspects infection, they should promptly notify the care team and initiate contact precautions. The Centers for Disease Control recommends gloves and gowns as personal protective equipment, as scabies spreads rapidly through skin-to-skin contact, especially at the wrists. Maintaining contact precautions until at least 24 hours after initiation of effective therapy is vital to protect healthcare workers and other patients in institutional settings.[15]

Education on scabies and its clinical presentation is essential for all healthcare providers involved in patient care, including those in primary care, emergency medicine, urgent care, pharmacy, and dermatology.[4] Pharmacists play a crucial role in guiding the appropriate use of topical therapies and, when necessary, compounding formulations with additional ingredients to optimize treatment and alleviate pruritus. 

Medication compliance should be encouraged, as treatment failures are often due to nonadherence to prescribed regimens. Nurses are typically on the front line for monitoring treatment adherence, reinforcing patient and family education, and identifying additional contacts who may require treatment. All healthcare providers share the responsibility of educating patients on environmental eradication measures within the home, which are essential to breaking the cycle of infestation.

Scabies remains a significant public health concern, and treatment failure is often linked to nonadherence to prescribed regimens. Preventive measures such as improving living conditions, reducing overcrowding, and avoiding the sharing of personal items can further decrease the risk of persistence and reinfestation. In endemic regions, community-wide interventions—including mass drug administration and coordinated public health campaigns—are essential to reducing transmission and controlling outbreaks.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Swe PM, Christian LD, Lu HC, Sriprakash KS, Fischer K. Complement inhibition by Sarcoptes scabiei protects Streptococcus pyogenes - An in vitro study to unravel the molecular mechanisms behind the poorly understood predilection of S. pyogenes to infect mite-induced skin lesions. PLoS Negl Trop Dis. 2017 Mar;11(3):e0005437. [PMC free article: PMC5360341] [PubMed: 28278252]

2.

Sharaf MS. Scabies: Immunopathogenesis and pathological changes. Parasitol Res. 2024 Mar 04;123(3):149. [PMC free article: PMC10909795] [PubMed: 38433167]

3.

Micali G, Lacarrubba F, Verzì AE, Chosidow O, Schwartz RA. Scabies: Advances in Noninvasive Diagnosis. PLoS Negl Trop Dis. 2016 Jun;10(6):e0004691. [PMC free article: PMC4911127] [PubMed: 27311065]

4.

Anderson KL, Strowd LC. Epidemiology, Diagnosis, and Treatment of Scabies in a Dermatology Office. J Am Board Fam Med. 2017 Jan 02;30(1):78-84. [PubMed: 28062820]

5.

Aždajić MD, Bešlić I, Gašić A, Ferara N, Pedić L, Lugović-Mihić L. Increased Scabies Incidence at the Beginning of the 21st Century: What Do Reports from Europe and the World Show? Life (Basel). 2022 Oct 13;12(10) [PMC free article: PMC9604680] [PubMed: 36295033]

6.

El-Moamly AA. Scabies as a part of the World Health Organization roadmap for neglected tropical diseases 2021-2030: what we know and what we need to do for global control. Trop Med Health. 2021 Aug 16;49(1):64. [PMC free article: PMC8366162] [PubMed: 34399850]

7.

Dressler C, Rosumeck S, Sunderkötter C, Werner RN, Nast A. The Treatment of Scabies. Dtsch Arztebl Int. 2016 Nov 14;113(45):757-762. [PMC free article: PMC5165060] [PubMed: 27974144]

8.

Talaga-Ćwiertnia K. Sarcoptes Infestation. What Is Already Known, and What Is New about Scabies at the Beginning of the Third Decade of the 21st Century? Pathogens. 2021 Jul 09;10(7) [PMC free article: PMC8308645] [PubMed: 34358018]

9.

Stamm LV, Strowd LC. Ignoring the "Itch": The Global Health Problem of Scabies. Am J Trop Med Hyg. 2017 Dec;97(6):1647-1649. [PMC free article: PMC5805045] [PubMed: 29016295]

10.

Vasanwala FF, Ong CY, Aw CWD, How CH. Management of scabies. Singapore Med J. 2019 Jun;60(6):281-285. [PMC free article: PMC6595060] [PubMed: 31243462]

11.

Engelman D, Yoshizumi J, Hay RJ, Osti M, Micali G, Norton S, Walton S, Boralevi F, Bernigaud C, Bowen AC, Chang AY, Chosidow O, Estrada-Chavez G, Feldmeier H, Ishii N, Lacarrubba F, Mahé A, Maurer T, Mahdi MMA, Murdoch ME, Pariser D, Nair PA, Rehmus W, Romani L, Tilakaratne D, Tuicakau M, Walker SL, Wanat KA, Whitfeld MJ, Yotsu RR, Steer AC, Fuller LC. The 2020 International Alliance for the Control of Scabies Consensus Criteria for the Diagnosis of Scabies. Br J Dermatol. 2020 Nov;183(5):808-820. [PMC free article: PMC7687112] [PubMed: 32034956]

12.

Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187. [PMC free article: PMC8344968] [PubMed: 34292926]

13.

Thomas C, Castillo Valladares H, Berger TG, Chang AY. Scabies, Bedbug, and Body Lice Infestations: A Review. JAMA. 2024 Sep 09; [PMC free article: PMC12132924] [PubMed: 39250129]

14.

Thadanipon K, Anothaisintawee T, Rattanasiri S, Thakkinstian A, Attia J. Efficacy and safety of antiscabietic agents: A systematic review and network meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2019 May;80(5):1435-1444. [PubMed: 30654070]

15.

Kandi V. Laboratory Diagnosis of Scabies Using a Simple Saline Mount: A Clinical Microbiologist's Report. Cureus. 2017 Mar 19;9(3):e1102. [PMC free article: PMC5398661] [PubMed: 28435762]

16.

Werbel T, Hinds BR, Cohen PR. Scabies presenting as cutaneous nodules or malar erythema: reports of patients with scabies surrepticius masquerading as prurigo nodularis or systemic lupus erythematosus. Dermatol Online J. 2018 Sep 15;24(9) [PubMed: 30677831]

Disclosure: Christine Ziebold declares no relevant financial relationships with ineligible companies.

Disclosure: Jonathan Crane declares no relevant financial relationships with ineligible companies.